Redmond Asset Management’s Aratana Therapeutics, Inc. PETX Stock Holding History

Redmond Asset Management’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-60,176	Closed	-$369K	–	169
2018 Q4	$369K	Sell	60,176 -514	-0.8%	-$3.14K	0.18%	138
2018 Q3	$354K	Buy	60,690 +3,594	+6%	+$18K	0.14%	149
2018 Q2	$243K	Hold	57,096	–	–	0.1%	158
2018 Q1	$252K	Buy	57,096 +680	+1%	+$3.03K	0.11%	157
2017 Q4	$297K	Buy	56,416 +475	+0.8%	+$2.91K	0.13%	153
2017 Q3	$343K	Hold	55,941	–	–	0.16%	139
2017 Q2	$404K	Buy	55,941 +1,500	+3%	+$9.22K	0.19%	129
2017 Q1	$289K	Buy	54,441 +554	+1%	+$3.74K	0.15%	140
2016 Q4	$387K	Buy	53,887 +215	+0.4%	+$1.74K	0.18%	138
2016 Q3	$502K	Buy	53,672 +200	+0.4%	+$1.66K	0.25%	116
2016 Q2	$338K	Hold	53,472	–	–	0.17%	127
2016 Q1	$295K	Buy	+53,472	New	+$201K	0.15%	126

Other funds holding PETX

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

GPGA

Grandeur Peak Global Advisors Salt Lake City, Utah $427M AUM 39.14% 1-Year Est. Return

Impax Asset Management Group London, United Kingdom $14.3B AUM 19.8% 1-Year Est. Return

Redmond Asset Management's PETX Position: Q1 2019 in Review

Redmond Asset Management sold out of Aratana Therapeutics, Inc. (PETX) in Q1 2019, closing a stake of 60,176 shares — an estimated $369K sold.

Redmond Asset Management first reported a position in PETX in Q1 2016 and held it in 12 quarters. The position peaked at $502K in Q3 2016. 104 funds tracked by Wall St. Rank hold PETX as of Q1 2019.

Redmond Asset Management reported no remaining Aratana Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
Redmond Asset Management sold 60,176 Aratana Therapeutics, Inc. shares in Q1 2019, an estimated $369K.
Redmond Asset Management first reported a position in Aratana Therapeutics, Inc. in Q1 2016 and held it in 12 quarters.
Redmond Asset Management's Aratana Therapeutics, Inc. position peaked at $502K in Q3 2016.
104 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q1 2019.

Based on Redmond Asset Management's 13F filing for Q1 2019, filed 24 Apr 2019.